Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 6/20 | 0.61 |
| ▸ | ACACA | Q13085 | 9/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14950652 | 0.91 | ACACB (0.56) | ACACBACACAADORA2BHDAC1HDAC11 | |
| SCHEMBL14945146 | 0.91 | ACACB (0.53) | ACACBACACAADORA2B | |
| SCHEMBL14945175 | 0.90 | ACACB (0.52) | ACACBACACAADORA2B | |
| SCHEMBL20672376 | 0.90 | ACACB (0.60) | ACACBACACAADORA2B | |
| SCHEMBL22994467 | 0.88 | ACACA (0.51) | ACACBACACAP2RX3ADORA2B | |
| SCHEMBL14945739 | 0.88 | ACACB (0.51) | ACACBACACAP2RX3ADORA2B | |
| SCHEMBL14950711 | 0.87 | ADORA2B (0.53) | ACACBACACAP2RX3ADORA2B | |
| SCHEMBL14945494 | 0.87 | ACACB (0.54) | ACACBACACAADORA2B | |
| SCHEMBL22994410 | 0.87 | ACACB (0.48) | ACACBACACAP2RX3ADORA2B | |
| SCHEMBL22144398 | 0.85 | ACACB (0.61) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4273132-A2 | PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF | Gilead Sciences, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-3589636-B1 | PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF | GILEAD SCIENCES INC (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-3329919-B1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO LLC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-9944655-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2015-07-23 | — | — | US | disclosed |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2015-07-23 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| WO-2013071169-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ACACB 2/4885ACACA 1/4885P2RX3 4770/4885 |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ACACB 2/4885ACACA 1/4885P2RX3 4770/4885 |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ACACB 2/4885ACACA 1/4885P2RX3 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.